Treating gliomas with glucocorticoids: from bedside to bench

[en] Glucocorticoids are used in the treatment of gliomas to decrease tumour-associated oedema and to reduce the risk of acute encephalopathy associated with radiotherapy. However, the mechanisms by which glucocorticoids work are still largely unknown. In this paper, we survey the experimental and clinical evidence for the effects of glucocorticoids on tumour cell proliferation, apoptosis and sensitivity to chemotherapy, angiogenesis and vascular permeability. We then review current guidelines on the choice of molecule, dose and duration of glucocorticoid treatment for gliomas.

Disciplines :

Pediatrics
Oncology
Neurology
Neurosciences & behavior

Author, co-author :

Piette, Caroline ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement

Munaut, Carine ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement

Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique

Deprez, Manuel ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

Language :

English

Title :

Treating gliomas with glucocorticoids: from bedside to bench

Publication date :

December 2006

Journal title :

Acta Neuropathologica

ISSN :

0001-6322

eISSN :

1432-0533

Publisher :

Springer Verlag, New York, United States - New York

Volume :

112

Issue :

Pages :

651-664

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 27 April 2009

Statistics

Number of views

180 (9 by ULiège)

Number of downloads

364 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Andersen C, Haselgrove JC, Doenstrup S, Astrup J, Gyldensted C (1993) Resorption of peritumoural oedema in cerebral gliomas during dexamethasone treatment evaluated by NMR relaxation time imaging. Acta Neurochir (Wien) 122:218-224
Andersen C, Jensen FT (1998) Differences in blood-tumour-barrier leakage of human intracranial tumours: Quantitative monitoring of vasogenic oedema and its response to glucocorticoid treatment. Acta Neurochir (Wien) 140:919-924
Andersen C, Taagehoj JF, Muhler A, Rehling M (1996) Approximation of arterial input curve data in MRI estimation of cerebral blood-tumor-barrier leakage: Comparison between Gd-DTPA and 99mTc-DTPA input curves. Magn Reson Imaging 14:235-241
Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM (2003) Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro-oncology 5:235-243
Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci (Lond) 94:557-572
Bastin ME, Carpenter TK, Armitage PA, Sinha S, Wardlaw JM, Whittle IR (2006) Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol 27:402-408
Beaney RP, Leenders KL, Brooks DJ (1987) Effects of dexamethasone in brain tumour patients. Lancet 1:571-572
Bell BA, Smith MA, Kean DM, McGhee CN, MacDonald HL, Miller JD, Barnett GH, Tocher JL, Douglas RH, Best JJ (1987) Brain water measured by magnetic resonance imaging. Correlation with direct estimation and changes after mannitol and dexamethasone. Lancet 1:66-69
Brightman MW, Reese TS (1969) Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40:648-677
Brooks DJ, Beaney RP, Lammertsma AA, Leenders KL, Horlock PL, Kensett MJ, Marshall J, Thomas DG, Jones T (1984) Quantitative measurement of blood-brain barrier permeability using rubidium-82 and positron emission tomography. J Cereb Blood Flow Metab 4:535-545
Cadepond F, Ulmann A, Baulieu EE (1997) RU486 (mifepristone), mechanisms of action and clinical uses. Annu Rev Med 48:129-156
Cairncross JG, Macdonald DR, Pexman JH, Ives FJ (1988) Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 38:724-726
Chang CC, Shinonaga M, Kuwabara T, Mima T, Shigeno T (1990) Effect of recombinant human lipocortin I on brain oedema in a rat glioma model. Acta Neurochir Suppl (Wien) 51:145-147
Costas MA, Muller IL, Holsboer F, Arzt E (2000) Transrepression of NF-kappaB is not required for glucocorticoid-mediated protection of TNF-alpha-induced apoptosis on fibroblasts. Biochim Biophys Acta 1499:122-129
Criscuolo GR, Lelkes PI, Rotrosen D, Oldfield EH (1989) Cytosolic calcium changes in endothelial cells induced by a protein product of human gliomas containing vascular permeability factor activity. J Neurosurg 71:884-891
Criscuolo GR, Merrill MJ, Oldfield EH (1988) Further characterization of malignant glioma-derived vascular permeability factor. J Neurosurg 69:254-262
Croxtall JD, Choudhury Q, Flower RJ (2000) Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 130:289-298
Das A, Banik NL, Patel SJ, Ray SK (2004) Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:BCl-2 ratio and preventing proteolytic activities. Mol Cancer 3:36
Del Maestro RF, Megyesi JF, Farrell CL (1990) Mechanisms of tumor-associated edema: A review. Can J Neurol Sci 17:177-183
Ellemann K, Christensen L, Gjerris F, Briand P, Kruse-Larsen C (1988) Glucocorticoid receptors in glioblastoma multiforme: A new approach to antineoplastic glucocorticoid therapy. Acta Neurochir (Wien) 93:6-9
Evans-Storms RB, Cidlowski JA (2000) Delineation of an antiapoptotic action of glucocorticoids in hepatoma cells: The role of nuclear factor-kappaB. Endocrinology 141:1854-1862
Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M (2000) Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol Rev 52:513-556
Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R (1995) Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol 131:1095-1103
Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M (1995) Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 13:112-123
Frappaz D, Chinot O, Bataillard A, Ben Hassel M, Capelle L, Chanalet S, Chatel M, Figarella-Branger D, Guegan Y, Guyotat J, Hoang-Xuan K, Jouanneau E, Keime-Guibert F, Laforet C, Linassier C, Loiseau H, Maire JP, Menei P, Rousmans S, Sanson M, Sunyach MP (2003) Summary version of the Standards, Options and Recommendations for the management of adult patients with intracranial glioma (2002). Br J Cancer 89(Suppl 1):S73-S83
Freshney RI, Sherry A, Hassanzadah M, Freshney M, Crilly P, Morgan D (1980) Control of cell proliferation in human glioma by glucocorticoids. Br J Cancer 41:857-866
Galicich JH, French LA, Melby JC (1961) Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet 81:46-53
Gametchu B (1987) Glucocorticoid receptor-like antigen in lymphoma cell membranes: Correlation to cell lysis. Science 236:456-461
Gametchu B, Chen F, Sackey F, Powell C, Watson CS (1999) Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models. Steroids 64:107-119
Gibelli N, Zibera C, Butti G, Assietti R, Sica G, Scerrati M, Iacopino F, Roselli R, Paoletti P, Robustelli della CG (1989) Hormonal modulation of brain tumour growth: A cell culture study. Acta Neurochir (Wien) 101:129-133
Gonzalez MV, Jimenez B, Berciano MT, Gonzalez-Sancho JM, Caelles C, Lafarga M, Munoz A (2000) Glucocorticoids antagonize AP-1 by inhibiting the activation/phosphorylation of JNK without affecting its subcellular distribution. J Cell Biol 150:1199-1208
Grasso RJ, Johnson CE (1977) Dose-response relationships between glucocorticoids and growth inhibition in rat glioma monolayer cultures. Proc Soc Exp Biol Med 154:238-241
Grasso RJ, Johnson CE, Boler RK, Moore NA (1977) Combined growth-inhibitory responses and ultrastructural alterations produced by 1,3-bis(2-chloroethyl)-1-nitrosourea and dexamethasone in rat glioma cell cultures. Cancer Res 37:585-594
Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, Mealey J Jr, Odom GL, Paoletti P, Ransohoff J, Robertson JT, Selker RG, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1983) Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67:121-132
Greenstein S, Ghias K, Krett NL, Rosen ST (2002) Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 8:1681-1694
Guerin C, Wolff JE, Laterra J, Drewes LR, Brem H, Goldstein GW (1992) Vascular differentiation and glucose transporter expression in rat gliomas: Effects of steroids. Ann Neurol 31:481-487
Hayashi R, Wada H, Ito K, Adcock IM (2004) Effects of glucocorticoids on gene transcription. Eur J Pharmacol 500:51-62
Horton J, Baxter DH, Olson KB (1971) The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 111:334-336
Hossmann KA (1989) The pathophysiology of experimental brain edema. Neurosurg Rev 12:263-280
Hughes MA, Parisi M, Grossman S, Kleinberg L (2005) Primary brain tumors treated with steroids and radiotherapy: Low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 62:1423-1426
Jacobsson J, Persson M, Hansson E, Ronnback L (2006) Corticosterone inhibits expression of the microglial glutamate transporter GLT-1 in vitro. Neuroscience 139:475-483
Jarden JO, Dhawan V, Moeller JR, Strother SC, Rottenberg DA (1989) The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: A positron emission tomographic study. Ann Neurol 25:239-245
Jondal M, Pazirandeh A, Okret S (2004) Different roles for glucocorticoids in thymocyte homeostasis? Trends Immunol 25:595-600
Kaup B, Schindler I, Knupfer H, Schlenzka A, Preiss R, Knupfer MM (2001) Time-dependent inhibition of glioblastoma cell proliferation by dexamethasone. J Neurooncol 51:105-110
Klatzo I (1967) Presidental address. Neuropathological aspects of brain edema. J Neuropathol Exp Neurol 26:1-14
Langeveld CH, Vanwaas MP, Stoof JC, Sutanto W, Dekloet ER, Wolbers JG, Heimans JJ (1992) Implication of glucocorticoid receptors in the stimulation of human glioma cell-proliferation by dexamethasone. J Neurosci Res 31:524-531
Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G (2004) Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 25:746-755
Leenders KL, Beaney RP, Brooks DJ, Lammertsma AA, Heather JD, McKenzie CG (1985) Dexamethasone treatment of brain tumor patients: Effects on regional cerebral blood flow, blood volume, and oxygen utilization. Neurology 35:1610-1616
Lieberman A, LeBrun Y, Glass P, Goodgold A, Lux W, Wise A, Ransohoff J (1977) Use of high dose corticosteroids in patients with inoperable brain tumours. J Neurol Neurosurg Psychiatry 40:678-682
Lindvall-Axelsson M, Owman C (1990) Actions of sex steroids and corticosteroids on rabbit choroid plexus as shown by changes in transport capacity and rate of cerebrospinal fluid formation. Neurol Res 12:181-186
Losel R, Wehling M (2003) Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4:46-56
Lu S, Ahn D, Johnson G, Cha S (2003) Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors. AJNR Am J Neuroradiol 24:937-941
MacDonald HL, Bell BA, Smith MA, Kean DM, Tocher JL, Douglas RH, Miller JD, Best JJ (1986) Correlation of human NMR T1 values measured in vivo and brain water content. Br J Radiol 59:355-357
Matsuoka Y, Hossmann KA (1981) Corticosteroid therapy of experimental tumour oedema. Neurosurg Rev 4:185-190
McEwan IJ, Wright AP, Gustafsson JA (1997) Mechanism of gene expression by the glucocorticoid receptor: Role of protein-protein interactions. Bioessays 19:153-160
McKay LI, Cidlowski JA (1999) Molecular control of immune/inflammatory responses: Interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20:435-459
McLean JS, Frame MC, Freshney RI, Vaughan PF, Mackie AE, Singer I (1986) Phenotypic modification of human glioma and non-small cell lung carcinoma by glucocorticoids and other agents. Anticancer Res 6:1101-1106
Mealey J Jr, Chen TT, Schanz GP (1971) Effects of dexamethasone and methylprednisolone on cell cultures of human glioblastomas. J Neurosurg 34:324-334
Morita K, Ishimura K, Tsuruo Y, Wong DL (1999) Dexamethasone enhances serum deprivation-induced necrotic death of rat C6 glioma cells through activation of glucocorticoid receptors. Brain Res 816:309-316
Morris GM, Micca PL, Coderre JA (2004) The effect of dexamethasone on the uptake of p-boronophenylalanine in the rat brain and intracranial 9L gliosarcoma. Appl Radiat Isot 61:917-921
Moutsatsou P, Kazazoglou T, Fleischer-Lambropoulos H, Psarra AM, Tsiapara A, Sekeris CE, Stefanis C, Vernadakis A (2000) Expression of the glucocorticoid receptor in early and late passage C-6 glioma cells and in normal astrocytes derived from aged mouse cerebral hemispheres. Int J Dev Neurosci 18:329-335
Nathoo N, Goldlust S, Vogelbaum MA (2004) Epidermal growth factor receptor antagonists: Novel therapy for the treatment of high-grade gliomas. Neurosurgery 54:1480-1488
Ohnishi T, Sher PB, Posner JB, Shapiro WR (1990) Capillary permeability factor secreted by malignant brain tumor. Role in peritumoral brain edema and possible mechanism for anti-edema effect of glucocorticoids. J Neurosurg 72:245-251
Oldendorf WH, Cornford ME, Brown WJ (1977) The large apparent work capability of the blood-brain barrier: A study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol 1:409-417
Orchinik M, Murray TF, Moore FL (1991) A corticosteroid receptor in neuronal membranes. Science 252:1848-1851
Paoletti P, Butti G, Zibera C, Scerrati M, Gibelli N, Roselli R, Magrassi L, Sica G, Rossi G, Dellacuna GR (1990) Characteristics and biological role of steroid-hormone receptors in neuroepithelial tumors. J Neurosurg 73:736-742
Pendergrass TW, Milstein JM, Geyer JR, Mulne AF, Kosnik EJ, Morris JD, Heideman RL, Ruymann FB, Stuntz JT, Bleyer WA (1987) Eight drugs in one day chemotherapy for brain tumors: Experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 5:1221-1231
Pinski J, Halmos G, Shirahige Y, Wittliff JL, Schally AV (1993) Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486. J Clin Endocrinol Metab 77:1388-1392
Renaudin J, Fewer D, Wilson CB, Boldrey EB, Calogero J, Enot KJ (1973) Dose dependency of decadron in patients with partially excised brain tumors. J Neurosurg 39:302-305
Rhodes CG, Wise RJ, Gibbs JM, Frackowiak RS, Hatazawa J, Palmer AJ, Thomas DG, Jones T (1983) In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 14:614-626
Rinehart J, Keville L, Measel J, Spiekerman AM, Burke K (1995) Corticosteroid alteration of carboplatin-induced hematopoietic toxicity in a murine model. Blood 86:4493-4499
Rinehart J, Keville L, Neidhart J, Wong L, DiNunno L, Kinney P, Aberle M, Tadlock L, Cloud G (2003) Hematopoietic protection by dexamethasone or granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients treated with carboplatin and ifosfamide. Am J Clin Oncol 26:448-458
Robe PA, Nguyen-Khac M, Jolois O, Rogister B, Merville MP, Bours V (2005) Dexamethasone inhibits the HSV-tk/ganciclovir bystander effect in malignant glioma cells. BMC Cancer 5:32
Roger T, Chanson AL, Knaup-Reymond M, Calandra T (2005) Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 35:3405-3413
Sarin R, Murthy V (2003) Medical decompressive therapy for primary and metastatic intracranial tumours. Lancet Neurol 2:357-365
Sasson R, Tajima K, Amsterdam A (2001) Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3-5-monophosphate and p53 activation in immortalized human granulosa cells:iNvolvement of Bcl-2. Endocrinology 142:802-811
Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11(Suppl 1):S45-S55
Shinoda J, McLaughlin KE, Bell HS, Swaroop GR, Yamaguchi S, Holmes MC, Whittle IR (2003) Molecular mechanisms underlying dexamethasone inhibition of iNOS expression and activity in C6 glioma cells. Glia 42:68-76
Shinonaga M, Chang CC, Kuwabara T (1990) Relation between macrophage infiltrates and peritumoral edema. Adv Neurol 52:475-481
Siegal T, Soti F, Biegon A, Pop E, Brewster ME (1997) Effect of a chemical delivery system for dexamethasone (Dex-CDS) on peritumoral edema in an experimental brain tumor model. Pharm Res 14:672-675
Sinha S, Bastin ME, Wardlaw JM, Armitage PA, Whittle IR (2004) Effects of dexamethasone on peritumoural oedematous brain: A DT-MRI study. J Neurol Neurosurg Psychiatry 75:1632-1635
Sinha S, Bastin ME, Whittle IR (2003) Rapid clinical deterioration in a patient with multi-focal glioma despite corticosteroid therapy: A quantitative MRI study. Br J Neurosurg 17:537-540
Solito E, Mulla A, Morris JF, Christian HC, Flower RJ, Buckingham JC (2003) Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology 144:1164-1174
Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, Hammond D (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 7:165-177
Stankova J, Turcotte S, Harris J, Rola-Pleszczynski M (2002) Modulation of leukotriene B4 receptor-1 expression by dexamethasone: Potential mechanism for enhanced neutrophil survival. J Immunol 168:3570-3576
Stellato C (2004) Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc 1:255-263
Sur P, Sribnick EA, Patel SJ, Ray SK, Banik NL (2005) Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells. Glia 50:160-167
Swaroop GR, Malcolm GP, Kelly PA, Ritchie I, Whittle IR (1998) Effects of nitric oxide modulation on tumour blood flow and microvascular permeability in C6 glioma. Neuroreport 9:2577-2581
Swaroops GR, Kelly PA, Holmes MC, Shinoda J, Whittle IR (2001) The effects of dexamethasone therapy on permeability, blood flow and iNOS expression in experimental glioma. J Clin Neurosci 8:35-39
Tamargo RJ, Leong KW, Brem H (1990) Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J Neurooncol 9:131-138
Tamargo RJ, Sills AK Jr, Reinhard CS, Pinn ML, Long DM, Brem H (1991) Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. J Neurosurg 74:956-961
Unterberg A, Schmidt W, Wahl M, Ellis EF, Marmarou A, Baethmann A (1991) Evidence against leukotrienes as mediators of brain edema. J Neurosurg 74:773-780
Unterberg A, Wahl M, Hammersen F, Baethmann A (1987) Permeability and vasomotor response of cerebral vessels during exposure to arachidonic acid. Acta Neuropathol (Berl) 73:209-219
Urbach V, Walsh DE, Mainprice B, Bousquet J, Harvey BJ (2002) Rapid non-genomic inhibition of ATP-induced Cl-secretion by dexamethasone in human bronchial epithelium. J Physiol 545:869-878
Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors:a randomized study of doses of 4, 8, and 16 mg per day. Neurology 44:675-680
Vielkind U, Walencewicz A, Levine JM, Bohn MC (1990) Type-II glucocorticoid receptors are expressed in oligodendrocytes and astrocytes. J Neurosci Res 27:360-373
Wang H, Li M, Rinehart JJ, Zhang R (2004) Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: In vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 10:1633-1644
Weller M, Schmidt C, Roth W, Dichgans J (1997) Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone? Neurology 48:1704-1709
Wessely O, Deiner EM, Beug H, von Lindern M (1997) The glucocorticoid receptor is a key regulator of the decision between self-renewal and differentiation in erythroid progenitors. EMBO J 16:267-280
Wolff JE, Denecke J, Jurgens H (1996) Dexamethasone induces partial resistance to cisplatinum in C6 glioma cells. Anticancer Res 16:805-809
Wolff JE, Jurgens H (1994) Dexamethasone induced partial resistance to methotrexate in C6-glioma cells. Anticancer Res 14:1585-1588
Wolff JE, Molenkamp G, Hotfilder M, Laterra J (1997) Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo. Klin Padiatr 209:275-277
Wolfson AH, Snodgrass SM, Schwade JG, Markoe AM, Landy H, Feun LG, Sridhar KS, Brandon AH, Rodriguez M, Houdek PV (1994) The role of steroids in the management of metastatic carcinoma to the brain. A pilot prospective trial. Am J Clin Oncol 17:234-238
Wright RL, Shaumba B, Keller J (1969) The effect of glucocorticosteroids on growth and metabolism of experimental glial tumors. J Neurosurg 30:140-145
Zhou J, Cidlowski JA (2005) The human glucocorticoid receptor: One gene, multiple proteins and diverse responses. Steroids 70:407-417
Zibera C, Gibelli N, Butti G, Pedrazzoli P, Carbone M, Magrassi L, Robustelli della CG (1992) Proliferative effect of dexamethasone on a human glioblastoma cell line (HU 197) is mediated by glucocorticoid receptors. Anticancer Res 12:1571-1574